<?xml-stylesheet type='text/xsl' href='anzctrTransform.xsl'?>
<ANZCTR_Trial requestNumber="343329">
  <stage>Registered</stage>
  <submitdate>11/08/2011</submitdate>
  <approvaldate>17/08/2011</approvaldate>
  <actrnumber>ACTRN12611000880943</actrnumber>
  <trial_identification>
    <studytitle>Safety &amp; Efficacy of Eculizumab to Prevent antibody mediated rejection in Living Donor Kidney Transplant Recipients Requiring Desensitization</studytitle>
    <scientifictitle>A randomised, open-label, multicentre trial to determine safety and efficacy of eculizumab in the prevention of antibody mediated rejection (AMR) in living donor kidney transplant recipients requiring desensitization therapy</scientifictitle>
    <utrn />
    <trialacronym />
    <secondaryid>clinicaltrials.gov identifier NCT01399593</secondaryid>
  </trial_identification>
  <conditions>
    <healthcondition>Kidney transplant</healthcondition>
    <conditioncode>
      <conditioncode1>Renal and Urogenital</conditioncode1>
      <conditioncode2>Kidney disease</conditioncode2>
    </conditioncode>
  </conditions>
  <interventions>
    <interventions>Patients will be randomised to standard of care or eculizumab.
Eculizumab will be administered by IV infusion over 45 minutes. There will be 9 doses of eculizumab over 9 weeks, with 1200mg intravenously just before transplant surgery, followed by 900mg dosed weekly for 4 weeks, then 1200mg administered fortnightly for 6 weeks.

Standard of Care: No Intervention. Patients will receive prophylactic therapy for AMR according to the hospital standard procedure post transplant.</interventions>
    <comparator>Eculizumab will be compared to standard of care using prophylactic treatments post transplantation.</comparator>
    <control>Active</control>
    <interventioncode>Treatment: drugs</interventioncode>
    <interventioncode>Prevention</interventioncode>
  </interventions>
  <outcomes>
    <primaryOutcome>
      <outcome>The primary composite endpoint is the Week 9 post-transplantation treatment failure rate defined as the occurrence of 1) biopsy-proven AMR, 2) graft loss, 3) patient death, or 4) loss to follow-up. The diagnosis of AMR will be based on kidney allograft 
The primary analysis of all endpoints will occur after all patients have reached Month 12 post-transplantation.</outcome>
      <timepoint>Endpoints will be assessed at week 9 post transplant.</timepoint>
    </primaryOutcome>
    <secondaryOutcome>
      <outcome>Cumulative incidence of AMR occurring between Week 9 and Month 12 post transplant.</outcome>
      <timepoint>Biopsies will be taken post reperfusion, at day 14, months 3 and 12. There will be another biopsy at month 36 post transplantation for long term follow up purposes.</timepoint>
    </secondaryOutcome>
  </outcomes>
  <eligibility>
    <inclusivecriteria>1.Male or female patients &gt;=18 years old
2.Patients with Stage IV or Stage V chronic kidney disease who will receive a kidney transplant from a living donor to whom they are sensitized and require desensitization prior to transplantation
3.Able to understand the informed consent form and willing to comply with study procedures</inclusivecriteria>
    <inclusiveminage>18</inclusiveminage>
    <inclusiveminagetype>Years</inclusiveminagetype>
    <inclusivemaxage>0</inclusivemaxage>
    <inclusivemaxagetype>No limit</inclusivemaxagetype>
    <inclusivegender>Both males and females</inclusivegender>
    <healthyvolunteer>No</healthyvolunteer>
    <exclusivecriteria>1.Hypersensitivity to eculizumab, to murine proteins or to one of the excipients
2.Any medical condition that, in the opinion of the Investigator, might interfere with the patient's participation in the study, poses an added risk for the patient, or confounds the assessment of the patient</exclusivecriteria>
  </eligibility>
  <trial_design>
    <studytype>Interventional</studytype>
    <purpose>Prevention</purpose>
    <allocation>Randomised controlled trial</allocation>
    <concealment>All patients who are desensitized and cleared for transplant by their doctor will be randomised 1:1 to either the treatment or SOC control arm. Randomisation will be performed centrally via internet.</concealment>
    <sequence>Patients will be randomised 1:1 utilising a web based randomisation system.</sequence>
    <masking>Open (masking not used)</masking>
    <assignment>Parallel</assignment>
    <designfeatures />
    <endpoint>Safety/efficacy</endpoint>
    <statisticalmethods />
    <masking1 />
    <masking2 />
    <masking3 />
    <masking4 />
    <patientregistry />
    <followup />
    <followuptype />
    <purposeobs />
    <duration />
    <selection />
    <timing />
  </trial_design>
  <recruitment>
    <phase>Phase 2</phase>
    <anticipatedstartdate>15/03/2012</anticipatedstartdate>
    <actualstartdate />
    <anticipatedenddate />
    <actualenddate />
    <samplesize>80</samplesize>
    <actualsamplesize />
    <recruitmentstatus>Recruiting</recruitmentstatus>
    <recruitmentcountry>Australia</recruitmentcountry>
    <recruitmentstate />
    <countryoutsideaustralia>
      <country>Canada</country>
      <state />
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>France</country>
      <state />
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>Germany</country>
      <state />
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>Italy</country>
      <state />
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>Norway</country>
      <state />
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>Netherlands</country>
      <state />
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>United States of America</country>
      <state />
    </countryoutsideaustralia>
  </recruitment>
  <sponsorship>
    <primarysponsortype>Commercial sector/Industry</primarysponsortype>
    <primarysponsorname>Alexion Pharmaceuticals Australasia Pty Ltd</primarysponsorname>
    <primarysponsoraddress>Suites 226-227, 117 Old Pittwater Road
Brookvale NSW 2100</primarysponsoraddress>
    <primarysponsorcountry>Australia</primarysponsorcountry>
    <fundingsource>
      <fundingtype>Commercial sector/Industry</fundingtype>
      <fundingname>Alexion Pharmaceuticals Australasia Pty Ltd</fundingname>
      <fundingaddress>Suites 226-227, 117 Old Pittwater Road
Brookvale NSW 2100</fundingaddress>
      <fundingcountry>Australia</fundingcountry>
    </fundingsource>
    <secondarysponsor>
      <sponsortype>None</sponsortype>
      <sponsorname />
      <sponsoraddress />
      <sponsorcountry />
    </secondarysponsor>
  </sponsorship>
  <ethicsAndSummary>
    <summary>Antibody mediated rejection post kidney transplant has become a significant clinical problem given that over 25% of kidney transplant candidates have antibodies to potential organ donors. There is no approved treatment for AMR and options to treat are limited. It is hoped that eculizumab will reduce the incidence of AMR post kidney transplantation in sensitized patients.</summary>
    <trialwebsite />
    <publication />
    <ethicsreview>Approved</ethicsreview>
    <publicnotes />
    <ethicscommitee>
      <ethicname>Royal Adelaide Hospital Research Ethics Committee</ethicname>
      <ethicaddress>Royal Adelaide Hosptial
North Terrace SA 5000</ethicaddress>
      <ethicapprovaldate>31/01/2012</ethicapprovaldate>
      <hrec>RAH Protocol No 111130</hrec>
      <ethicsubmitdate>24/08/2011</ethicsubmitdate>
      <ethiccountry>Australia</ethiccountry>
    </ethicscommitee>
    <ethicscommitee>
      <ethicname>Melbourne Health Human Research Ethics Committee</ethicname>
      <ethicaddress>Office for Research
Level 6 East, Main Building
300 Grattan Street
The Royal Melbourne Hospital 
Parkville VIC 3050</ethicaddress>
      <ethicapprovaldate />
      <hrec />
      <ethicsubmitdate>23/09/2011</ethicsubmitdate>
      <ethiccountry>Australia</ethiccountry>
    </ethicscommitee>
    <ethicscommitee>
      <ethicname>SLHD Ethics Review Committee (RPAH Zone)</ethicname>
      <ethicaddress>c/- Research Development Office
Royal Prince Alfred Hospital
Missenden Road
CAMPERDOWN NSW 2050</ethicaddress>
      <ethicapprovaldate />
      <hrec />
      <ethicsubmitdate>13/02/2012</ethicsubmitdate>
      <ethiccountry>Australia</ethiccountry>
    </ethicscommitee>
    <ethicscommitee>
      <ethicname>Southern Health Human Research Ethics Committee</ethicname>
      <ethicaddress />
      <ethicapprovaldate />
      <hrec />
      <ethicsubmitdate />
      <ethiccountry>Australia</ethiccountry>
    </ethicscommitee>
  </ethicsAndSummary>
  <attachment />
  <contacts>
    <contact>
      <title>Ms</title>
      <name>Cheryl Townsend</name>
      <address>Alexion Pharmaceuticals Australasia Pty Ltd Suites 226-227, 117 Old Pittwater Road Brookvale NSW 2100</address>
      <phone>+61 2 9091 0500</phone>
      <fax>+61 2 9091 0511</fax>
      <email>townsendc@alxn.com</email>
      <country>Australia</country>
      <type>Scientific Queries</type>
    </contact>
    <contact>
      <title>Ms</title>
      <name>Catherine Rowland</name>
      <address>Alexion Pharmaceuticals Australasia Pty Ltd Suites 226-227, 117 Old Pittwater Road Brookvale NSW 2100</address>
      <phone>+61 2 9091 0500</phone>
      <fax>+61 2 9091 0511</fax>
      <email>rowlandc@alxn.com</email>
      <country>Australia</country>
      <type>Public Queries</type>
    </contact>
    <contact>
      <title />
      <name>Catherine Rowland</name>
      <address>Alexion Pharmaceuticals Australasia Pty Ltd Suites 226-227, 117 Old Pittwater Road Brookvale NSW 2100</address>
      <phone>+61 2 9091 0500</phone>
      <fax>+61 2 9091 0511</fax>
      <email>rowlandc@alxn.com</email>
      <country>Australia</country>
      <type>Updating Information</type>
    </contact>
    <contact>
      <title>Prof</title>
      <name>Graeme Russ</name>
      <address>Renal Unit, Level 9 East Wing
Royal Adelaide Hosptial
North Terrace SA 5000</address>
      <phone>618 8222 0932</phone>
      <fax />
      <email>graeme.russ@health.sa.gov.au</email>
      <country>Australia</country>
      <type>Principal Investigator</type>
    </contact>
  </contacts>
</ANZCTR_Trial>